CO6400229A2 - Construcciones de casb7439 - Google Patents

Construcciones de casb7439

Info

Publication number
CO6400229A2
CO6400229A2 CO11165849A CO11165849A CO6400229A2 CO 6400229 A2 CO6400229 A2 CO 6400229A2 CO 11165849 A CO11165849 A CO 11165849A CO 11165849 A CO11165849 A CO 11165849A CO 6400229 A2 CO6400229 A2 CO 6400229A2
Authority
CO
Colombia
Prior art keywords
seq
immunogenic composition
tlr
agonist
excipient
Prior art date
Application number
CO11165849A
Other languages
English (en)
Inventor
Normand Blais
Martine Harvey
Clement Rioux
Anthony Pilorget
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6400229A2 publication Critical patent/CO6400229A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una construcción de proteína que comprende un polipéptido CASB7439 modificado seleccionado a partir de: (a) LVL055 (SEQ ID NO: 1); (b) LVL111 (SEQ ID NO: 3); (c) LVL137 (SEQ ID NO: 5); (d) LVL141 (SEQ ID NO: 7); (e) LVL144 (SEQ ID NO: 9); y (f) LVL168 (SEQ ID NO: 11).2.- Una composición inmunogénica, la cual comprende la construcción de la proteína de la reivindicación 1, y un vehículo o excipiente farmacéuticamente aceptable, en donde el vehículo o excipiente puede comprender opcionalmente un regulador.3.- La composición inmunogénica de la reivindicación 2, la cual comprende además un adyuvante.4.- La composición inmunogénica de la reivindicación 3, en donde el adyuvante comprende cuando menos uno de: un agonista de TLR-4, una fracción de saponina inmunológicamente activa, un agonista de TLR-9.
CO11165849A 2009-05-27 2011-12-01 Construcciones de casb7439 CO6400229A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US22039609P 2009-06-25 2009-06-25

Publications (1)

Publication Number Publication Date
CO6400229A2 true CO6400229A2 (es) 2012-03-15

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11165849A CO6400229A2 (es) 2009-05-27 2011-12-01 Construcciones de casb7439

Country Status (19)

Country Link
US (1) US8916514B2 (es)
EP (1) EP2435469A1 (es)
JP (1) JP2012528106A (es)
KR (1) KR20120014054A (es)
CN (1) CN102459324B (es)
AU (1) AU2010252012A1 (es)
BR (1) BRPI1012078A2 (es)
CA (1) CA2763486A1 (es)
CL (1) CL2011002994A1 (es)
CO (1) CO6400229A2 (es)
DO (1) DOP2011000348A (es)
EA (1) EA020617B1 (es)
IL (1) IL216351A0 (es)
MA (1) MA33409B1 (es)
MX (1) MX2011012623A (es)
NZ (1) NZ596501A (es)
PE (1) PE20120400A1 (es)
SG (1) SG176220A1 (es)
WO (1) WO2010136443A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
EP2266603B1 (en) * 2000-10-18 2012-09-12 GlaxoSmithKline Biologicals S.A. Tumour vaccines
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
US20190255165A1 (en) * 2016-09-21 2019-08-22 Amal Therapeutics Sa Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015763A1 (en) 1992-02-18 1993-08-19 Smithkline Beecham Corporation Vaccinal polypeptides
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TR199801531T2 (xx) 1996-02-09 1998-10-21 Smithkline Beecham Biologicals S.A. Zoster vir�s geni ve �r�n�ne kar�� a��lar.
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DE69933200T2 (de) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
EP1290217A2 (en) 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
CA2400842C (en) * 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0104259D0 (en) 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
GB0111974D0 (en) 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
EP1575515A4 (en) 2002-08-29 2007-08-08 Genentech Inc ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
US20080108070A1 (en) 2006-09-08 2008-05-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Also Published As

Publication number Publication date
IL216351A0 (en) 2012-01-31
CN102459324A (zh) 2012-05-16
BRPI1012078A2 (pt) 2019-09-24
SG176220A1 (en) 2011-12-29
US8916514B2 (en) 2014-12-23
US20120070491A1 (en) 2012-03-22
CA2763486A1 (en) 2010-12-02
CL2011002994A1 (es) 2012-07-20
CN102459324B (zh) 2014-07-09
WO2010136443A1 (en) 2010-12-02
EA020617B1 (ru) 2014-12-30
NZ596501A (en) 2013-11-29
PE20120400A1 (es) 2012-05-04
KR20120014054A (ko) 2012-02-15
EP2435469A1 (en) 2012-04-04
MA33409B1 (fr) 2012-07-03
JP2012528106A (ja) 2012-11-12
AU2010252012A1 (en) 2011-12-22
DOP2011000348A (es) 2012-01-15
MX2011012623A (es) 2011-12-14
EA201190274A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
CO6400229A2 (es) Construcciones de casb7439
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
MX362698B (es) Metodo novedoso y composiciones.
PE20120543A1 (es) Anticuerpo anti-tau ps422
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
WO2009022154A3 (en) Peptide with multiple epitopes
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
TW200745334A (en) Compositions and methods for producing a composition
NZ618391A (en) Antigenic tau peptides and uses thereof
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2010129895A3 (en) Cd133 epitopes
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
CO6470858A2 (es) Composición tensioactiva reconstituida mejorada que contiene análogos de la proteína tensioactiva b (sp-b) y de la proteína tensioactiva c (sp-c)
MX348622B (es) Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
ES2627117T3 (es) Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
EA201000327A1 (ru) Белок
WO2009125231A3 (en) Anti-atheroma vaccine
WO2010003691A3 (en) BIOCONJUGATES COMPRISING Aβ-AUTOANTIBODY SPECIFIC EPITOPES FOR ACTIVE IMMUNOTHERAPY AND DIAGNOSIS OF ALZHEIMER'S DISEASE
DOP2010000056A (es) Un antigeno de malaria para vacunar contra la malaria
NZ597442A (en) Hyr1 as a target for active and passive immunization against candida
EA201100071A1 (ru) Новые композиции и способы
WO2008134665A8 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
HK1106027A1 (en) Immunogenic glycopeptides for diagnosing pathogenic microorganisms infections

Legal Events

Date Code Title Description
FG Application granted